Wound and burn treatment biotech PolyNovo was placed in a trading halt on Friday afternoon, pending an announcement regarding clearance by the US Food and Drug Administration for a “major new product” for the US market.

The business, which is one of the top 20 most shorted ASX stocks, is trading down almost 39 per cent in the past month, after investors were disappointed in its full-year earnings figures.